Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOADAPT: Neoadjuvant AI + Pertuzumab/Trastuzumab in Breast Cancer
NCT02689921Phase 2Unknown
- Sponsor
- City of Hope Chicago
- Start
- Apr 2016
- Primary completion
- Dec 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pertuzumab and trastuzumab in breast cancer, sponsored by City of Hope Chicago. Primary endpoint: Pathological Response at 1 year. Status: unknown.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02689921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02689921.